Clinical Application of Intracranial Pressure Monitoring Based on Flash Visual Evoked Potential in Treatment of Patients with Hypertensive Intra-cerebral HemorrhageAuthor(s): ZHAO Ying-Chun*, Zhang Yu, Wu Ying and YU Fang-ping
Objective: To investigate the application value of Flash Visual Evoked Potential (FVEP) non-Invasive Intracranial Pressure (nICP) monitoring technology in patients with Hypertensive Intra-cerebral Hemorrhage (HICH).
Methods: There were 116 eligible subjects included in the experiment; the final sample size was 102 for this study. They were randomly divided into FVEP nICP monitoring group (experimental group) and the non-monitoring group (control group). The experimental group was examined lumbar puncture immediately after intracranial pressure was monitored by FVEP. Mannitol was used in reducing the elevated intracranial pressure. The serum concentrations of creatinine and urea nitrogen were recorded to assess the renal function. To evaluate the efficacy of FVEP nICP monitoring technique for clinical adjustment of mannitol. The Glasgow Prognosis Scores (GOS) were evaluated for patients' prognosis between two groups.
Results: There was no statistical significance between FVEP nICP measurement and lumbar puncture intracranial pressure measurement (195.76 ± 58.88 mm H2O vs. 197.04 ± 53.72 mm H2O, P>0.05). Linear correlation analysis indicated that there was a strong positive relationship between the measurements (r=0.950, P<0.01). The duration prescription time and the average usage amount of mannitol in the experimental group was significantly less than that in the control group (P<0.05), and the serum creatinine and urea nitrogen concentrations in the two groups were not statistically significant (P>0.05). The cure rate of the experimental group was higher than that of the control group (χ²=3.889, P=0.048).
Conclusion: FVEP nICP monitoring technology could replace invasive intracranial pressure monitoring technology in part HICH patients. The application of FVEP nICP technique can reduce the dosage of mannitol and improve the prognosis of patients with HICH.